Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous technique, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://josephf430ceg1.blogcudinti.com/profile